ALZpath sells $8.4M in equity after licensing Alzheimer's antibody to Abbott
The Carlsbad diagnostics developer has $2 million left to sell as partners build tests around its pTau217 reagent.
By Ryan Merket · Published
Primary source: SEC EDGAR
Why it matters
ALZpath is financing the costly step between scientific validation and regulated distribution, while Abbott, Roche, Siemens and Beckman build tests around its antibody.
ALZpath, the Alzheimer's diagnostics developer co-founded by S. Venkat Shastri, Jerre Stead and Eric Reiman, disclosed an $8.41 million equity sale in a Form D filed with the Securities and Exchange Commission on July 21st.…
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.